ReviewChemical Society reviews2017
The development of anticancer ruthenium(ii) complexes: from single molecule compounds to nanomaterials.
Review in Chemical Society reviews, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 214 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
214 citing papers in PubMed.
- UV photo-uncaging of Ru(II)-polypyridyl bioconjugates in high vacuum.Physical chemistry chemical physics : PCCP · 2026Article
- A Ruthenium-BODIPY Photosensitizer for Light-Triggered Apoptosis in Triple-Negative Breast Cancer Cells.Inorganic chemistry · 2026Article
- Folate-Targeted Liposomal Delivery of a Ru(II)-Based Photosensitizer for Photodynamic Tumor Therapy via Pyroptosis Induction.Advanced healthcare materials · 2026Article
- Ruthenium(ii) polypyridyl complexes and the DNA damage response: mechanisms and therapeutic implications.RSC medicinal chemistry · 2026Review
- Synthesis, characterisation and antibacterial activity of flavone-based Sn(iv) and Sb(iii) complexes.RSC advances · 2026Article
- Mechanistic insights into the anticancer potential of ruthenium(II) paracymene complexes of phenolic acids.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Metal complexes in medicine: structural scaffoldsChemical science · 2026Review
- Liposomal Delivery of Cell Impermeable Phototoxic Ru(II) Complexes.Chembiochem : a European journal of chemical biology · 2026Article
- Ru-Based NSAIDs as Potential Anticancer Therapeutics.Molecules (Basel, Switzerland) · 2026Article
- A novel metal-organic coordination polymer based on Ru complexes for photoredox catalysis and photodynamic therapy of breast cancer.Materials today. Bio · 2026Article
- High Cytotoxicity of Ruthenium(II) and Gold(I) Bimetallic Complexes and Its Precursors.Inorganic chemistry · 2026Article
- ADMET Profiling of the Metallodrugs: A Comparative Review of Platinum, Palladium, Gold, Ruthenium, Copper, and Zinc Anticancer Complexes.Bioinorganic chemistry and applications · 2026Review
- DNA Noncovalent Interactions of Dinuclear ηChemistry (Weinheim an der Bergstrasse, Germany) · 2025Article
- Playing with Structural Parameters in the Design of Ruthenium(II)-Inorganic chemistry · 2025Article
- FALCON-qPCR: a new method for the quantification of oxidative lesions in mitochondrial DNA.Bioanalysis · 2025Article
- DNA Binding Study of a Redox Active Enantiopure Bis(arylimino)acenaphthene (BIAN) Os(II) Bipyridine Complex.Chembiochem : a European journal of chemical biology · 2025Article
- Design and synthesis of bioactive Ru(ii) complexes: antibacterial activity, biocompatibility and biomolecular binding.RSC advances · 2025Article
- Hybrid Materials Based on Reduced Graphene Oxide; Synthesis and Characterization of V and Ru Metal Complexes.Journal of fluorescence · 2025Article
- Novel tryptophan 2,3-dioxygenase-targeted ruthenium(ii)-indole complex activates immunotherapyChemical science · 2025Article
- Bilosomal Encapsulation of Binuclear Phosphino Ru(II)-Cu(II) Compounds Enhances Their Selectivity and Activity toward Lung and Prostate Cancers.Journal of medicinal chemistry · 2025Article
154 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Cancer is rapidly becoming the top killer in the world. Most of the FDA approved anticancer drugs are organic molecules, while metallodrugs are very scarce. The advent of the first metal based therapeutic agent, cisplatin, launched a new era in the application of transition metal complexes for therapeutic design. Due to their unique and versatile biochemical properties, ruthenium-based compounds have emerged as promising anti-cancer agents that serve as alternatives to cisplatin and its derivertives. Ruthenium(iii) complexes have successfully been used in clinical research and their mechanisms of anticancer action have been reported in large volumes over the past few decades. Ruthenium(ii) complexes have also attracted significant attention as anticancer candidates; however, only a few of them have been reported comprehensively. In this review, we discuss the development of ruthenium(ii) complexes as anticancer candidates and biocatalysts, including arene ruthenium complexes, polypyridyl ruthenium complexes, and ruthenium nanomaterial complexes. This review focuses on the likely mechanisms of action of ruthenium(ii)-based anticancer drugs and the relationship between their chemical structures and biological properties. This review also highlights the catalytic activity and the photoinduced activation of ruthenium(ii) complexes, their targeted delivery, and their activity in nanomaterial systems.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.